

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_80031
Title of the Manuscript:	<b>Comparative Study of Efficacy of Jatamansi (Nardostachys jatamansi DC) and Imipramine in Generalized Anxiety Disorder (G.A.D.) – A Randomized Controlled Double Blind Clinical Trial</b>
Type of the Article	<b>Study Protocol</b>

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

**Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<p><b>Introduction :</b></p> <ul style="list-style-type: none"> <li>• need to add literature review on the negatives of modern medicine and why need to turn to TCM</li> <li>• what is the active ingredients of jatamansi responsible for the anxiolytic effect?</li> <li>• anxiolytic effect of jatamansi - reference for this?</li> </ul> <p><b>Objectives :</b> Need to define the objectives accurately...overlap between the objective</p> <p><b>Data collection :</b></p> <ul style="list-style-type: none"> <li>• Inaccurate...computer generated is the NOT how sample is collected</li> <li>• Participants enrollment – not clear from where</li> </ul> <p><b>Study design</b></p> <ul style="list-style-type: none"> <li>• How is the “blinding” done?</li> <li>• computer generated Simple Random – Is this the randomization process or collection process</li> </ul> <p><b>Sample size:</b></p> <ul style="list-style-type: none"> <li>• unclear - How is it determined...based on what parameters?</li> </ul> <p><b>Inclusion criteria</b></p> <ul style="list-style-type: none"> <li>• Freshly diagnosed- need to define What does this mean...within weeks vs months?</li> </ul> <p><b>Exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• Patients with no history of medications - Not clear...do you exclude pt who has no history of medications</li> </ul> <p><b>Dose of imipramine</b> - 75 mg HS – what does HS mean  <b>Any withdrawal</b> criteria and how will this be handled  <b>Safety measurement</b>...how is it done?</p> <p>The overall protocol require English editing as there many issues with grammar and sentence structure.</p>	
<b><u>Minor</u></b> REVISION comments		
<b><u>Optional/General</u></b> comments	<p>The study overall has potential. However, need to improve on the overall methodology and needs further English editing.</p>	

**Review Form 1.6**

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

As per the guideline of editorial office we have followed VANCOUVER reference style for our paper.

Kindly see the following link:

<http://sciencedomain.org/archives/20>

**Reviewer Details:**

Name:	<b>Lili Husniati Yaacob</b>
Department, University & Country	<b>University of Science, Malaysia</b>